Avion Pharmaceuticals sought approval of its NDA for Oral Contraceptive Balcoltra

Makers of the the Prenate line of prescription prenatal vitamins, Avion Pharmaceuticals sought approval of its New Drug application for the Oral Contraceptive Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) to be rolled out in 2018.

Balcoltra is a branded oral contraceptive combining 0.1 mg levonorgestrel, 20 mcg ethinyl estradiol tablets and ferrous bisglycinate tablets 36.5 mg paving way for women to access oral contraception thereby empowering them.

Art Deas, CEO of Avion said “Avion is excited to offer our women’s health community this oral contraceptive formulation that fills a gap in the current branded options available to women.”